




Abstract The Nerve-Growth Factor Signaling in Gender-Related Cancers⁺

Marzia Di Donato ^{1,*}, Giovanni Galasso ¹, Gustavo Cernera ², Antimo Migliaccio ¹, and Gabriella Castoria ¹

- ¹ Department of Precision Medicine, University of Campania "L.Vanvitelli", 80138 Naples, Italy; giovanni.galasso@unicampania.it (G.G.); antimo.migliaccio@unicampania.it (A.M.); gabriella.castoria@unicampania.it (G.C.)
- ² Department of Molecular Medicine and Medical Biotechnology, University of Naples "Federico II", 80131 Naples, Italy; gustavo.cernera@unina.it
- Correspondence: marzia.didonato@unicampania.it
- Presented at Cells, Cells and Nothing but Cells: Discoveries, Challenges and Directions, 6–8 March 2023; Available online: https://sciforum.net/event/cells2023.

Abstract: The nerve-growth factor (NGF) was initially identified as a promoter of neuronal survival and differentiation. As such, it has captured the interest of neurobiologists for a long time. Nowadays, NGF is considered a multifaceted molecule with pleiotropic effects in quite divergent cell types, including hormone-dependent cancer cells. Many tumors exhibit derangements of nerve-growth factor and its receptors, including the tropomyosin receptor kinase A (TrkA). This receptor is frequently expressed in triple-negative breast cancers (TNBC), as well as prostate cancers (PC), although its role in the pathogenesis and aggressiveness of these diseases is still under investigation. We now report that the treatment of TNBC as well as PC-derived cells with NGF triggers the proliferation and survival of these cells. Simultaneously, NGF fosters cell motility and induces invasiveness in these cells by acting on the release of metalloproteases-9 (MMP-9). The somatic knockdown of TrkA or its pharmacologic inhibition by the specific inhibitor GW441756 impair these effects. A strong reduction in TNBC or PC-derived spheroid size is observed upon GW441756 treatment. The relevance of our studies is based on the novelty that further exploration of NGF pathway derangements in gender-related cancers will likely offer innovative targets and treatment opportunities in the clinical management of TNBC as well as PC patients.

Keywords: prostate cancer; triple-negative breast cancer; NGF/TrkA signaling



Funding: This research was funded by Italian Ministry of University and Scientific Research (P.R.I.N. 2017EKMFTN_002 to G.C. (Gabriella Castoria)) Regione Sicilia (Progetto di Ricerca Finalizzata RF-2019-12368937 to A.M.) and Vanvitelli Young Researcher (PATG.Rice.Base.GiovaniRicercatori2022. IDEA to M.D.D.).

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: Not applicable.

Conflicts of Interest: The authors declare no conflict of interest.

Disclaimer/Publisher's Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.



Citation: Di Donato, M.; Galasso, G.; Cernera, G.; Migliaccio, A.; Castoria, G. The Nerve-Growth Factor Signaling in Gender-Related Cancers. *Biol. Life Sci. Forum* **2023**, *21*, 4. https://doi.org/10.3390/blsf2023021004

Academic Editor: Alexander E. Kalyuzhny

Published: 17 March 2023



Copyright: © 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https:// creativecommons.org/licenses/by/ 4.0/).